Chronic & Non-Communicable Disease

Chronic and non-communicable disease is the sub-domain where the verification cycle's principal substantive corrections operate at the IRA Medicare Drug Price Negotiation Program level and are reinforced at the cross-cutting Braidwood and FDA RIF / CTP layers. The IRA program is operative under the Trump administration through EO 14273 (April 15, 2025) modification framing. Round 1 (10 drugs) prices took effect January 1, 2026 with CMS projecting approximately $6 billion in Medicare net Year-1 savings (approximately 22% reduction) and approximately $1.5 billion in beneficiary out-of-pocket savings at the negotiated [Maximum Fair Price](/paul/campaign/empower/glossary/#mfp). The 10 drugs span cardiovascular (Eliquis, Xarelto, Entresto), diabetes (Jardiance, Januvia, Farxiga, NovoLog/Fiasp), autoimmune (Enbrel, Stelara), and oncology (Imbruvica). Round 2 (15 drugs) MFPs were announced approximately late November 2025 with prices effective January 1, 2027 (CMS Administrator Mehmet Oz framed savings as 44% / $12B net). Round 3 selections in early 2026 carry the [OBBBA](/paul/campaign/empower/glossary/#obbba) orphan-drug exclusion expansion that likely delayed Keytruda (Merck) and Opdivo (BMS) selections. The Braidwood SCOTUS resolution preserves USPSTF chronic-disease screening protections nationwide — cancer screenings, statin recommendations, BP screening, A1C screening all remain mandate-protected. The FDA [Center for Tobacco Products](/paul/campaign/empower/glossary/#ctp) is protected by the Rhode Island injunction; the menthol withdrawal RIN 0910-AI60 (January 21, 2025) proceeded.

Legal Architecture

Constitutional foundation

The chronic-disease architecture rests on the same federal Spending Clause plus 14th Amendment foundation as the broader public-health architecture. Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (June 27, 2025) preserves the ACA § 2713 preventive-services mandate including USPSTF A/B chronic-disease screening recommendations.

Federal statutory layer

ACA § 2713, 42 U.S.C. § 300gg-13. Preventive services no-cost-sharing requirement. Statutory stability: HIGH; administrative vulnerability: LOW post-Braidwood (mandate upheld nationwide June 27, 2025).

IRA Medicare Drug Price Negotiation Program — Inflation Reduction Act § 11001 (P.L. 117-169). Statutory stability: HIGH; administrative vulnerability: MODERATE — program continues under Trump EO 14273 modifications.

IRA Round 1 (effective January 1, 2026). The 10 selected drugs: Eliquis (apixaban; blood thinner), Jardiance (empagliflozin; diabetes/heart), Xarelto (rivaroxaban; blood thinner), Januvia (sitagliptin; diabetes), Farxiga (dapagliflozin; diabetes/heart/kidney), Entresto (sacubitril/valsartan; heart failure), Enbrel (etanercept; autoimmune), Imbruvica (ibrutinib; cancer), Stelara (ustekinumab; autoimmune), and NovoLog/Fiasp (insulin aspart; diabetes). MFPs were announced August 15, 2024; negotiated discounts range from 38% to 79% off list price (Entresto at 53% reduction; Enbrel at 60% or more). CMS projects approximately $6 billion in net Medicare Year-1 savings (approximately 22% reduction) and approximately $1.5 billion in beneficiary out-of-pocket savings under the defined-standard benefit design. ASPE utilization data shows 13% of non-LIS Medicare enrollees used at least one selected drug in 2022 (vs. 18% of LIS enrollees); the "11%" figure cited in some prior framing appears to derive from a different methodological metric. Standard 17 governmental-score note: the D12 verified cycle (May 1, 2026) supplements this finding with the CBO February 2026 baseline as supplementary citation; the CMS architectural finding stands as primary.

IRA Round 2 (effective January 1, 2027) — three relevant dates. Drug list announced January 17, 2025 (Biden administration's last days); MFPs announced approximately late November 2025 (CMS Administrator Mehmet Oz framed as 44% / $12 billion net savings); prices effective January 1, 2027. The 15 Round 2 drugs include blockbuster diabetes / weight-loss drugs per Medicare Rights Center reporting.

IRA Round 3 (effective January 1, 2028) — in progress. 15 Part B plus Part D drugs selected early 2026. First year for Part B physician-administered drugs in negotiation and first year of OBBBA orphan-drug exclusion expansion in effect. Per KFF March 2026 update, OBBBA changes likely delayed Keytruda (Merck) and Opdivo (BMS) selections that were expected based on Medicare spending levels. The OBBBA orphan-drug exclusion broadening (1) makes orphan drugs designated for multiple rare diseases ineligible for negotiation, not just single-rare-disease orphan drugs, and (2) delays the 7-year / 11-year period before negotiation eligibility for orphan drugs receiving non-orphan FDA approval.

Tobacco Control Act / FSPTCA, P.L. 111-31. Statutory stability: HIGH; administrative vulnerability: MODERATE — CTP capacity protected by the Rhode Island injunction; CTP menthol withdrawal RIN 0910-AI60 (January 21, 2025) proceeded.

OBBBA orphan-drug exclusion expansion (One Big Beautiful Bill Act, July 4, 2025). Broadens orphan-drug exclusion from IRA negotiation. Statutory stability: HIGH (newly enacted); administrative vulnerability: MODERATE — interpretation interacts with IRA Round 3 selections.

Trump EO 14273 (April 15, 2025; "Lowering Drug Prices by Once Again Putting Americans First"). Directs HHS Secretary to (1) improve MDPNP transparency; (2) prioritize high-cost drug selection; (3) minimize negative impacts on innovation. IRA negotiation continues with modifications directed; Round 1 effective; Round 2 finalized; Round 3 in progress. Trump signaled support for IRA negotiations in late January 2025 before issuing EO 14273 in April with modification directives.

CDC PLACES (Population Level Analysis and Community Estimates). Chronic-disease estimates at census-tract, ZCTA, and county level. Administrative vulnerability: MODERATE — currency partially unverified post-FDA-RIF and MAHA reorganization.

Federal agency layer

CMS Center for Medicare administers the Medicare Drug Price Negotiation Program. HHS / ASPE publishes utilization analyses. FDA Center for Tobacco Products administers tobacco regulation under FSPTCA, protected by the Rhode Island injunction. CDC NCCDPHP / PLACES operates chronic-disease surveillance.

State statutory layer and state agency layer

PA Cancer Control Plan continues operative. PA Cancer Registry at the Department of Health, Bureau of Health Statistics — currency partially unverified at the sub-domain level. PA DOH Bureau of Health Promotion and Risk Reduction administers chronic-disease programs.

Local statutory and local agency layer

Philadelphia Sweetened Beverage Tax (Philadelphia Code Title 19, Chapter 19-4100) continues operative. Philadelphia Tobacco Retailer Licensing (Philadelphia Code Title 6, Chapter 6-300) continues operative. PDPH Bureau of Chronic Disease Prevention administers local-level chronic-disease programs.

Cross-cutting structural features

Feature 1 — IRA Round 1 produces real but bounded savings. Round 1 savings reach is bounded by the ASPE-documented approximately 13% non-LIS / approximately 18% LIS utilization rate of selected drugs in 2022. PA-3 Medicare beneficiaries actually using the 10 selected drugs receive direct savings; beneficiaries who do not use the 10 selected drugs do not receive direct savings. The structural bound is a program-design feature, not an implementation gap.

Feature 2 — Braidwood preserves USPSTF chronic-disease screening durably. Cancer screenings (cervical, colorectal, lung, breast), statin recommendations for primary prevention, BP screening, and A1C diabetes screening — all USPSTF A/B services — remain mandate-protected nationwide. For PA-3 patients with ACA-compliant insurance including Medicaid managed care, the no-cost-sharing structure for USPSTF-recommended preventive services continues durably.

Feature 3 — CTP capacity is the second cross-cutting court-protection finding. The Rhode Island injunction's August 12, 2025 narrowed scope retained FDA Center for Tobacco Products protection. The menthol withdrawal RIN 0910-AI60 (January 21, 2025) proceeded; downstream litigation status is partially unverified.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: North Philadelphia Medicare beneficiary using IRA Round 1 drug

Constituent type: a Medicare-eligible adult resident in a North/Northwest Philadelphia Core tract (a sub-area with high cardiovascular and diabetes prevalence), with cardiovascular disease (atrial fibrillation; eligible for Eliquis) or type-2 diabetes with cardiovascular comorbidity (eligible for Jardiance), enrolled in Medicare Part D (non-LIS or LIS).

Pathway through the institutional system. Round 1 prices effective January 1, 2026. CMS MFP publication → Part D plan formulary integration → pharmacy dispensing at MFP-anchored cost-sharing under the defined-standard benefit design. Round 1 negotiated discounts range 38% to 79%; CMS projects approximately $1.5 billion aggregate beneficiary OOP savings; ASPE indicates approximately 13% of non-LIS and approximately 18% of LIS Medicare enrollees used at least one Round 1 drug in 2022.

Outcome. The constituent's per-fill cost-sharing for Eliquis or Jardiance drops materially under MFP-anchored pricing. Aggregate beneficiary savings are bounded by the share of beneficiaries actually using the 10 selected drugs.

Profile 2: Citywide PA-3 patient on Braidwood-preserved USPSTF cancer screening

Constituent type: an ACA-compliant-insured adult PA-3 resident (any sub-area) eligible for USPSTF A/B-recommended cancer screenings — cervical (women 21-65), colorectal (45-75), lung (50-80 with smoking history), breast (women 40-74).

Pathway through the institutional system. Primary-care visit with screening order under USPSTF guidelines. ACA § 2713 plus USPSTF A/B → no-cost-sharing for in-network screening → diagnosis / treatment pathway if abnormal. Braidwood resolved June 27, 2025; mandate upheld nationwide.

Outcome. The patient receives the recommended screening without cost-sharing; the protection is durable post-Braidwood.

Profile 3: West Philadelphia chronic-disease patient with hypertension and diabetes

Constituent type: an ACA-compliant-insured adult PA-3 resident (Medicaid managed care or marketplace) in a West Philadelphia Core tract with documented hypertension and type-2 diabetes, receiving primary care from a Federally Qualified Health Center (cross-reference the Health Access sub-domain).

Pathway through the institutional system. Annual primary-care visit with USPSTF-recommended BP screening, A1C screening, and statin recommendation (USPSTF A/B services). ACA § 2713 plus USPSTF → no-cost-sharing for screening → statin prescription with formulary coverage → ongoing management.

Outcome. The patient receives no-cost-sharing screening and chronic-disease management consistent with USPSTF recommendations. The Braidwood resolution preserves the USPSTF mandate nationwide; statin coverage continues.

Conversational note

Chronic and non-communicable disease is the sub-domain where the verification cycle's principal substantive corrections operate at the IRA-program level and are reinforced at the cross-cutting Braidwood and FDA RIF / CTP layers. The IRA Medicare Drug Price Negotiation Program is operative under the Trump administration through Trump EO 14273's modification framing. Round 1 (10 drugs) prices took effect January 1, 2026, with CMS projecting $6 billion Medicare net savings and $1.5 billion beneficiary OOP savings in the first year. The 10 drugs span cardiovascular (Eliquis, Xarelto, Entresto), diabetes (Jardiance, Januvia, Farxiga, NovoLog/Fiasp), autoimmune (Enbrel, Stelara), and oncology (Imbruvica) — matching the high-Medicare-spending pattern. For PA-3 Medicare beneficiaries actually using these drugs, the savings are real; but the population reach is bounded by the ASPE-documented 13% non-LIS / 18% LIS utilization rate of selected drugs in 2022.

Round 2 (15 drugs) timing requires three separate dates that prior framing sometimes conflated: drug list announced January 17, 2025 (Biden last days); MFPs announced approximately late November 2025 (CMS Administrator Mehmet Oz framed the savings as 44% / $12 billion net); prices effective January 1, 2027. Round 3 (15 Part B plus Part D drugs) selections in early 2026 carry the OBBBA orphan-drug interaction: per KFF March 2026, the OBBBA July 2025 expansion of the orphan-drug exclusion likely delayed Keytruda and Opdivo selections that would otherwise have been expected based on Medicare spending levels.

The Braidwood resolution preserves USPSTF chronic-disease screening protections nationwide. Cancer screenings, statin recommendations, BP screening, and A1C screening — all USPSTF A/B services — remain mandate-protected. For PA-3 patients with ACA-compliant insurance including Medicaid managed care, the no-cost-sharing structure for USPSTF-recommended preventive services continues durably.

The FDA CTP capacity for tobacco regulation is protected by the Rhode Island injunction; the menthol withdrawal RIN 0910-AI60 (January 21, 2025) proceeded. Downstream litigation status is partially unverified. The PA Cancer Control Plan continues operative without verification-cycle change at the framework level; PA Cancer Registry currency is partially unverified. Philadelphia Sweetened Beverage Tax and Philadelphia Tobacco Retailer Licensing continue operative.

The cross-cutting Standard 17 governmental-score handling is operative here. The D12 verified cycle (May 1, 2026) introduced CBO February 2026 baseline material that supplements the primary architectural finding for IRA Round 1; the CMS finding stands as the primary reference, and the D12-derived baseline is preserved as supplementary citation with explicit comparator notation (different metric; different window; different methodology).

The aggregate signal is that the federal chronic-disease policy architecture is operating with court-imposed checks on the most aggressive elements (Braidwood preserving the preventive-services mandate; Rhode Island injunction protecting CTP) and selective program continuation (IRA Round 1 effective; Trump EO 14273 directing modifications without dismantling). For PA-3 Medicare beneficiaries, the IRA Round 1 effective-date is the principal operational change in the verification window; the savings reach is bounded by utilization patterns.

Geography & representation

Data provenance. IRA Round 1 specifics (10 drugs; MFP discounts 38-79%; Entresto 53%; Enbrel ≥60%; CMS projections of approximately $6 billion net Year-1 savings and approximately $1.5 billion beneficiary OOP savings) are from CMS Newsroom Fact Sheet, KFF, and Medicare Rights Center. Round 2 dates (list January 17, 2025; MFPs late November 2025; effective January 1, 2027) and Round 3 status are from CMS, KFF March 2026 update, and Medicare Rights Center. ASPE 13% non-LIS / 18% LIS utilization figure is from ASPE published analysis. Braidwood (606 U.S. 748, June 27, 2025) is documented in the SCOTUS opinion. CTP protection under the Rhode Island injunction is documented in court filings; menthol withdrawal RIN 0910-AI60 (January 21, 2025) is documented in the Federal Register. The "11%" non-LIS coinsurance figure cited in some prior framing is flagged for source-citation precision. PA Cancer Registry currency for PA-3-specific tracts, HEDIS chronic-disease HealthChoices reporting currency, and FDA CTP menthol-withdrawal downstream litigation status are flagged for institutional-source retrieval.

PA-3 statistical profile. Chronic-disease prevalence in PA-3 historically concentrates in North/Northwest Philadelphia Core (cardiovascular disease; diabetes; hypertension) and West Philadelphia Core (similar pattern with strong overlap with the Medicaid-eligible population). PA-3 Medicare beneficiary distribution skews older; IRA Round 1 savings reach is bounded by the approximately 13% non-LIS / approximately 18% LIS utilization rate of selected drugs. PA Cancer Plan mortality data at city level historically shows higher cancer-mortality rates in North/Northwest Philadelphia Core; tract-level disaggregation for PA-3 was not located in the verification cycle.

Geographic variation.

North/Northwest Philadelphia Core. Heaviest chronic-disease burden; substantial Medicare beneficiary population; high prevalence of cardiovascular disease, diabetes, hypertension.
West Philadelphia Core. Substantial chronic-disease burden overlapping with Medicaid-eligible adult population; FQHC-pathway access to USPSTF screening (cross-reference the Health Access sub-domain).
Northwest Philadelphia. Somewhat lower chronic-disease prevalence; substantial Medicare beneficiary population.
South/Southwest Philadelphia. Mixed pattern; tract-level disaggregation not located in the verification cycle.

Specific tract-level chronic-disease prevalence figures and Medicare beneficiary IRA Round 1 utilization figures for PA-3 sub-areas were not located in the verification cycle. Sub-area patterns are presented as structural inference; specific sub-area-level prevalence or utilization figures are not asserted.

Pathway tracing.

USPSTF chronic-disease screening (Braidwood-protected). ACA § 2713 plus USPSTF A/B recommendations → no-cost-sharing in ACA-compliant plans → cancer screenings (cervical, colorectal, lung, breast); BP screening; A1C diabetes screening; statin recommendation for primary prevention. Pathway breakdown points: none currently — Braidwood resolved; mandate upheld.
IRA Round 1 Medicare drug pricing (effective January 1, 2026). CMS Center for Medicare published MFPs August 15, 2024; Round 1 prices effective January 1, 2026; 10 drugs. PA-3 Medicare beneficiaries who use the 10 selected drugs receive direct savings. Pathway breakdown points: Trump EO 14273 directs program modifications; selective preservation under political pragmatism; ASPE source-citation precision for the utilization-rate figure.
IRA Round 2 (effective January 1, 2027). Drug list announced January 17, 2025; MFPs announced approximately late November 2025; prices effective January 1, 2027; 15 drugs. Pathway breakdown points: enacted dates carry forward; OBBBA orphan-drug expansion does not retroactively affect Round 2.
IRA Round 3 (effective January 1, 2028) plus OBBBA interaction. 15 Part B plus Part D drugs selected early 2026. First year for Part B physician-administered drugs in negotiation; first year of OBBBA orphan-drug exclusion expansion in effect. Pathway breakdown points: OBBBA changes likely delayed Keytruda and Opdivo selections; cancer patients on these drugs continue to face non-negotiated prices through subsequent IRA windows.
FDA CTP regulatory pathway. FSPTCA → FDA CTP → menthol cigarette withdrawal RIN 0910-AI60 (January 21, 2025). CTP capacity protected by the Rhode Island injunction; downstream litigation status partially unverified.
PA Cancer Control Plan operational pathway. PA DOH operates the Cancer Control Plan; PA Cancer Registry collects data at state level. Pathway breakdown points: PA Cancer Registry currency partially unverified.
Philadelphia local chronic-disease prevention. Philadelphia Sweetened Beverage Tax plus Philadelphia Tobacco Retailer Licensing → consumer-pricing and access-restriction effects.

Representation question. The federal framework promises PA-3 chronic-disease patients USPSTF-recommended preventive services without cost-sharing under ACA § 2713, Medicare drug pricing negotiation under IRA Rounds 1, 2, 3, FDA CTP regulation of tobacco products under FSPTCA, PA Cancer Plan coordination at the state level, and Philadelphia local prevention infrastructure (SSB Tax; Tobacco Retailer Licensing). As of mid-2026, PA-3 constituents receive: USPSTF preventive services preserved nationwide (Braidwood resolved); IRA Round 1 prices effective for 10 drugs (PA-3 Medicare beneficiaries using these drugs receive negotiated-price savings, with reach bounded by approximately 13% non-LIS / approximately 18% LIS utilization rates); FDA CTP protected by the Rhode Island injunction; menthol withdrawal proceeded; PA Cancer Plan continues at framework level; PA Cancer Registry currency partially unverified. Two structural mechanisms account for the gap: the IRA Round 1 utilization-rate bound (beneficiaries who do not use the 10 selected drugs do not receive direct savings — a program-design feature, not an implementation gap), and limited PA-3-specific tract-level prevalence and utilization data (city-level and federal-level data does not consistently disaggregate to PA-3 sub-areas). PA-3 chronic-disease patients receive the framework-level protections that the federal architecture promises, with two material substantive findings: Braidwood preserves the durable USPSTF preventive-services pathway, and IRA Round 1 produces real but bounded savings for the subset of Medicare beneficiaries using the 10 selected drugs. The representation gap operates at the program-reach level (IRA bounded by utilization patterns) and at the data-availability level (PA-3 sub-area disaggregation) rather than at the framework level.

Gap analysis

Gap 1 — USPSTF preventive services plus chronic-disease screening (G2-SD4-01). Braidwood-resolved; mandate upheld. Cancer screenings, statin recommendations, BP screening, A1C screening — all USPSTF A/B services remain mandate-protected.

Gap 2 — Braidwood-dependent treatment access for chronic disease (G2-SD4-02). Closed: the ACA § 2713 mandate is upheld nationwide; cancer screenings, statin recommendations, BP screening, A1C screening all remain mandate-protected.

Gap 3 — IRA MFP first-round savings reach (G2-SD4-03). Round 1 verified effective with 10 drugs; CMS savings projections approximately $6 billion net Year-1 plus approximately $1.5 billion beneficiary OOP. ASPE utilization figure (13% non-LIS / 18% LIS) is the source-citation-precise figure; the "11%" referenced in some prior framing is flagged for source-citation precision. The structural bound is the share of beneficiaries actually using the 10 selected drugs.

Gap 4 — CTP rule-making capacity vs. FDA RIF (G2-SD4-04). CTP is protected by the Rhode Island injunction; the menthol withdrawal proceeded; downstream litigation status is partially unverified. The structural concern is that the broader FDA RIF (treated in the Public Health Infrastructure & Governance sub-domain) reduces the agency's overall regulatory capacity even where CTP itself is injunction-protected.

Gap 5 — OBBBA orphan-drug exclusion impact on IRA selection (G2-SD4-05). Confirmed: Keytruda and Opdivo delayed in Round 3 per KFF March 2026 update. Cancer patients on these drugs continue to face non-negotiated prices through subsequent IRA windows. The OBBBA orphan-drug exclusion broadening makes orphan drugs designated for multiple rare diseases ineligible for negotiation and delays the 7-year / 11-year period before negotiation eligibility for orphan drugs receiving non-orphan FDA approval.

Gap 6 — PA Cancer Plan operational structure (G2-SD4-06). PA Cancer Control Plan framework is confirmed; PA Cancer Registry currency for PA-3-specific tracts is partially unverified at the sub-domain level.